October 28, 2010
Scientists Raise Concerns About Flame
RetardantsFlame retardants used in a
wide range of consumer products pose a threat to human health and
may not even be all that effective, according to a statement signed
by nearly 150 scientists from 22 countries.
PTSD Linked to 'Hyperactivity' in Right BrainWEDNESDAY, Oct. 27 (HealthDay News) The flashbacks experienced
by people with post-traumatic stress disorder (PTSD) are associated
with heightened activity on the right side of the brain, a new
study finds.
U.S. Preschoolers Getting Too Much Screen Time:
StudyTwo-thirds of preschoolers
in the United States are exposed to more than the maximum two hours
per day of screen time from television, computers, video games and
DVDs recommended by the American Academy of Pediatrics, a new study
has found.
Early Humans More Advanced Than ThoughtTHURSDAY, Oct. 28 (HealthDay News) Early humans were using a
highly skilled stone tool sharpening method 75,000 years ago in
Africa, more than 50,000 years earlier than previously believed, a
new study indicates.
Concerns Grow Over Dangers of Caffeinated Alcohol
DrinksThe debate over the
dangers of alcoholic energy drinks, popular among the young because
they are inexpensive and carry the added punch of caffeine, has
intensified after students at colleges in New Jersey and Washington
state became so intoxicated they wound up in the hospital.
More Older Americans Living With HIVBetter treatments are
extending the lives of people with HIV, but aging with the
AIDS-causing virus takes a toll that will challenge the health care
system, a new report says.
Sprycel Approval Expanded to Include Rare
LeukemiaSprycel (dasatinib) has
received an additional approval from the U.S. Food and Drug
Administration to treat a rare form of blood cancer called
Philadelphia chromosome positive chronic phase chronic myeloid
leukemia (Ph+ CP -CML), the agency said Thursday in a news
release.
Latuda Approved for Adult SchizophreniaLurasidone HCI (Latuda)
tablets have been approved by the U.S. Food and Drug Administration
to treat adult schizophrenia, which affects about 1 percent of the
nation's adult population in a given year, the agency said Thursday
in a news release.